Exclusive: Schrödinger CEO 'couldn't be more pleased to be wrong' in launch of AI agent Bunsen. Senior biopharma correspondent. Three years ago, Schrödinger CEO Ramy Farid ruffled some feathers by pushing back on the AI fever of the moment. He said... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Simcere and Schrödinger enter global drug discovery and development collaboration. Release time:2026-07-10 July 10, 2026 - Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into a global drug discovery and development collaboration with Schrödinger, Inc. to advance an innovative program based on unmet clinical needs and Simcere's therapeutic area expertise. Zhou Gaobo, Chief Investment Officer of Simcere said: "We are delighted to establish a strategic collaboration with Schrödinger, a global leader in computational drug discovery. This partnership deeply integrates Schrödinger's world-leading computational platform and drug design expertise with Simcere's efficient research and development and commercialization platform. We look forward to leveraging our complementary strengths and collaborative innovation to accelerate the discovery, development and commercialization of cutting-edge therapies and bring more effective treatment options to patients worldwide." Karen Akinsanya, President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships of Schrödinger commented: "We are pleased to initiate this strategic collaboration with Simcere to jointly discover and develop innovative medicines to address significant unmet clinical needs. This agreement builds on our successful model of discovering innovative clinical candidates for high-value targets. By combining our track record in predict-first differentiated drug design with Simcere's excellent reputation for innovative R&D and clinical development execution globally, we aim to accelerate the discovery and development of therapies for patients around the world." Schrödinger, leveraging its industry-leading physics-based platform and expertise, will lead computational drug design and optimization for the joint research collaboration. Simcere will lead subsequent preclinical and clinical development following completion of the joint discovery phase. Schrödinger is eligible to receive discovery, development and commercial milestones for all programs in the collaboration, as well as tiered royalties on net sales. About Simcere Simcere Pharmaceutical Group Limited(2096.HK)is a pharmaceutical company driven by innovation and focusing on four therapeutic areas including Neuroscience, Oncology, Autoimmune Diseases and Anti-infection. Simcere Pharmaceutical Group proactively explore areas with significant unmet needs, and its mission is 'For patients, for life'. Driven by its in-house R&D efforts and synergistic innovation, Simcere has established strategic cooperation partnerships with many innovative companies and research institutes. Learn more atwww.simcere.com. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schrödinger has approximately 900 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow Simcere Pharmaceutical Group on LinkedIn, or visit its blog, Extrapolations.com.

Schrodinger Inc, a software provider for drug discovery and material science, reported 12% year-on-year growth in annual contract value to $28.4 million in Q1 2026. The company is transitioning to a hosted software licensing model, which caused software revenue to decline 21%, whilst drug discovery revenue more than doubled to $22.9 million. For full-year 2026, Schrodinger expects annual contract value between $218 million and $228 million, representing 10% to 15% growth, with drug discovery revenue projected at $55 million to $65 million. The company anticipates Q2 2026 annual contract value of $19 million to $23 million. Schrodinger shares have risen approximately 13% over the past month and are backed by 31 hedge funds, including the Bill & Melinda Gates Foundation Trust.